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Ho and colleagues1 studied the cross-sectional associations
between common systemic medication use and intraocular
pressure (IOP) in the Singapore Epidemiology of Eye Dis-
eases (SEED) study of a population-based cohort. Examining
associations with systemic
medications is of interest for
2 main reasons. First, under-
standing such associations may guide our management of
patients with glaucoma who are receiving treatment for sys-
temic comorbidities. Second, unexpected associations may
point to previously unknown biological mechanisms under-
lying the regulation of IOP, which may in turn lead to new
treatments.
In their report, Ho and colleagues state that “participants
taking systemicβ-blockershad lower IOPs.Conversely, theuse
of systemic ACEIs [angiotensin-converting enzyme inhibi-
tors], ARBs [angiotensin receptor blockers], statins, and sul-
fonylureas was associated with higher IOP.”1 The finding of
lower IOP inpeople takingoral β-blockerswasexpected, given
the extensive laboratory and clinic-based literature, and on a
population level, this replicates a previous report on partici-
pants of the European Prospective Investigation Into Cancer
(EPIC)–Norfolk Eye Study.2 The EPIC study examined the re-
lationshipbetween IOP inparticipantsusingACEIs,ARBs, stat-
ins, and sulfonylureas but did not find a significant associa-
tion toward either higher or lower readings. Comparing the
details of the analyticalmethods and results inEPICandSEED
data, one can see differences and similarities.
Both EPIC and SEED analyses carried out multiple statis-
tical tests. The SEED study examined the association be-
tween IOP and 22 different classes of drugs. Especially given
the exploratorynature of the study, itwouldbeprudent to ad-
just the threshold for statistical significance to reduce thepos-
sibility of false-positive chance findings. For example, a Bon-
ferroni adjustment for 22 statistical tests brings the threshold
for statistical significance at the 5% level to P < .002. In the
EPIC-NorfolkEyeStudy,95%CIswereused toquantify thepre-
cision of the effect size. In the SEED study, the probability of
all theeffects fallswithin the rangewhereachance findingcan-
not bediscounted, once one considers thepotential impact of
multiple statistical testing (ACEIs,P = .01; ARBs,P = .03; stat-
ins, P = .03; sulfonylureas, P = .02), and 95%CIswere not ap-
plied. Considering the Singapore data in isolation in a proba-
bilistic analysis, the scientific case for theputative association
must be seen as unproven. If one were to take a Bayesian ap-
proach,or tometa-analyzeEPICandSEEDdata, the resultsmay
be different.
While the EPIC data contrasts with the results from the
SEEDstudy, pointing tonoassociationbetween IOPandeither
ACEIs or ARBs, and a lower IOP in those using statins (−0.31
mm Hg [95% CI, −0.51 to −0.12]; P = .002), both the EPIC-
Norfolk Eye Study and the SEED studydid identify a trend to-
ward higher IOP in people using sulfonylureas (0.67 mm Hg
in theEPIC-NorfolkEyeStudy [P = .03] and0.34mmHg in the
SEEDstudy [P = .02]). Questions therefore arise regarding the
potential explanation(s) for such an association. The Rotter-
damEye Study reported an IOP thatwas 0.31mmHg (95%CI,
0.12-0.50mmHg)higher inpersonswithdiabetes than inper-
sons without diabetes.3 On the basis that the simplest expla-
nation is probably the right one, the association between sul-
fonylurea use and higher IOP is most plausibly explained by
drug use being a marker of diabetes status and its associated
phenotype.
The relationshipbetweendiabetes, IOP, andglaucomarisk
has puzzled ophthalmologists for decades.4 The association
betweendiabetesandhigher IOPseemsbeyondquestion.How-
ever, clinic-basedstudies reportingahigherprevalenceofglau-
coma among persons with diabetes are nowwidely regarded
as the result of ascertainmentbias.Multiple longitudinal stud-
ies showno increased riskofprimaryopen-angle glaucoma for
personswithdiabetes.4 Ithasbeensuggestedthatdiabetesmay
actually be protective against the effects of increased IOP by
acting to decrease the risk of glaucoma.4,5 There are indeed
good reasonswhy thismaybe true.4However, anequallyplau-
sible explanation is that measurement error is at least par-
tially responsible for thepuzzling coexistenceof increased IOP
and no increased risk of primary open-angle glaucoma. It is
known that the eyes of persons with diabetes have more col-
lagen cross-linking as a result of higher concentrations of ad-
vanced glycation end products,6 therefore resulting in me-
chanically stiffer corneas.
In a recent analysis of IOP in a very large cohort of pre-
dominantly white participants from the UK Biobank, amodi-
fied air-pulse tonometer (Ocular Response Analyzer; Rei-
chert Technologies) was used to examine IOP measures
calibrated tomatch the “industry standard”Goldmannappla-
nationtonometer (ie, theGoldmann-correlatedIOP[IOPg]),and
these IOPmeasureswerecomparedwith thoseadjusted for the
effectsofvariation incornealbiomechanicalproperties (ie, cor-
neal-compensated IOP [IOPcc]). Among 110573people, itwas
noted that IOPg measures were 0.41 mm Hg (95% CI, 0.30-
0.52mmHg) higher among thosewho self-reported that they
were diabetic (P < .001) but that the IOPcc measures were no
different between persons with diabetes and persons with-
out diabetes (−0.05 mm Hg [95% CI, −0.15 to 0.05 mm Hg];
P = .38).7 Of note, there is a similarity in the effect sizes ob-
served inEPICandSEEDparticipants takingsulfonylureas (0.67
mmHg in the EPIC-Norfolk Eye Study and 0.34mmHg in the
SEED study) and the IOPg difference between thosewith and
thosewithoutdiabetes in theUKBiobankcohort (0.41mmHg).
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Taken in the broader context, this offers an argument that the
true IOP in persons with diabetes is probably little different
from that of the population without diabetes.
Thismeandifference in IOPbetween thosewithand those
without diabetes is relatively small on an individual level, but
when one considers that the percentage of people with dia-
betes indifferentcountries ishighandincreasingrapidly (10.5%
of all adults in Singapore, 7.4% in the United Kingdom, and
12.3% in the United States), such an IOP measurement error
may influencedecisions to treat increased IOP inmanypeople.
This reiterates themessage that IOPalone isapoor tool for iden-
tifyingwhether an individual has glaucoma, and thereforede-
tection of this important cause of preventable blindness re-
quiresacareful assessmentofall relevant risk factors, anexpert
examination of the optic disc, and an assessment of the vi-
sual field.
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